FDA Requests Removal of All Ranitidine Products (Zantac) from the Market

FDA Advises Consumers, Patients and Health Care Professionals After New FDA Studies Show Risk to Public Health

Lab tests found Zantac contained levels of a cancer causing chemical NDMA 3100 times greater than the FDA’s accepted safe limit. The popular heart burn medication has now been recalled.

The FDA found NDMA in ranitidine, best known by the brand name Zantac, and warned the public in September 2019 of the potential risks and to consider alternative OTC and prescription treatments.  At the time, the agency did not have enough scientific evidence to recommend whether individuals should continue or stop taking ranitidine.  With today’s announcement, the FDA is sending letters to all manufacturers of ranitidine, best known by the brand name Zantac, requesting they withdraw their products from the market.  The FDA is also advising consumers taking OTC ranitidine, to stop taking any tablets or liquid they currently have, dispose of them properly and not buy more; for those who wish to continue treating their condition, they should consider using other approved OTC products for heartburn.  Patients taking prescription ranitidine should speak with their health care professional about other treatment options before stopping the medicine, as there are multiple drugs approved for the same or similar uses as ranitidine, that do not carry the same risks from NDMA.

If you took Zantac at least twice a week for a 6 month period or more, and you developed one of the cancers listed below, we think you may have a case.

Get a free case evaluation if you or a loved one took Zantac and developed one of the following cancers:

• Leukemia
• Bladder Cancer
• Esophageal Cancer
• Kidney Cancer
• Lung Cancer
• Pancreatic Cancer
• Stomach Cancer
• Breast Cancer
• Colorectal Cancer
• Intestinal Cancer
• Liver Cancer
• Ovarian Cancer
• Uterine Cancer

Don’t Wait Dial 210-888-8888!  Or email us at help@waynewright.com